We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+14.09%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$79.1B
AUM Growth
+$7.99B
(+11%)
Cap. Flow
-$5.86B
Cap. Flow
% of AUM
-7.4%
Top 10 Holdings %
Top 10 Hldgs %
22.63%
Holding
2,061
New
445
Increased
504
Reduced
465
Closed
231
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sysco
SYY
|
+$273M |
| 2 |
Waste Management
WM
|
+$168M |
| 3 |
Lowe's Companies
LOW
|
+$160M |
| 4 |
PNC Financial Services
PNC
|
+$154M |
| 5 |
Unilever
UL
|
+$122M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$548M |
| 2 |
Apple
AAPL
|
+$372M |
| 3 |
CSX Corp
CSX
|
+$369M |
| 4 |
Infosys
INFY
|
+$238M |
| 5 |
Kimberly-Clark
KMB
|
+$235M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.16% |
| 2 | Healthcare | 14.65% |
| 3 | Financials | 13.08% |
| 4 | Industrials | 9.66% |
| 5 | Consumer Discretionary | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Equinix
EQIX
$103B
| $199K | ﹤0.01% |
279
-1,128
| -80% | -$840K |
|
|
PAE
952
DELISTED
PAE Incorporated Class A Common Stock
PAE
| $198K | ﹤0.01% |
+21,667
| New | +$200K |
|
953
Sprott Physical Gold and Silver Trust
CEF
$8.06B
| $195K | ﹤0.01% |
10,126
| – | – |
|
954
Sprouts Farmers Market
SFM
$8.01B
| $195K | ﹤0.01% |
9,745
-137,096
| -93% | -$2.81M |
|
|
CUB
955
DELISTED
Cubic Corporation
CUB
| $193K | ﹤0.01% |
+3,123
| New | +$190K |
|
956
Twist Bioscience
TWST
$7.25B
| $191K | ﹤0.01% |
1,358
-645
| -32% | -$71.6K |
|
957
Alliant Energy
LNT
$18B
| $189K | ﹤0.01% |
3,672
-101,477
| -97% | -$5.46M |
|
|
ICPT
958
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $189K | ﹤0.01% |
7,653
+7,004
| +1,079% | +$232K |
|
959
Assurant
AIZ
$14.3B
| $188K | ﹤0.01% |
+1,387
| New | +$179K |
|
960
Green Brick Partners
GRBK
$3.14B
| $182K | ﹤0.01% |
7,957
+700
| +10% | +$14.6K |
|
961
Gentex
GNTX
$5.07B
| $178K | ﹤0.01% |
5,252
+5,189
| +8,237% | +$160K |
|
962
McCormick & Company Non-Voting
MKC
$14.2B
| $178K | ﹤0.01% |
1,871
-1,685
| -47% | -$159K |
|
963
NiSource
NI
$20.4B
| $178K | ﹤0.01% |
+7,817
| New | +$183K |
|
|
ONC
964
BeOne Medicines Ltd
ONC
$38.7B
| $178K | ﹤0.01% |
689
| – | – |
|
965
Willis Towers Watson
WTW
$32B
| $177K | ﹤0.01% |
841
| – | – |
|
966
Fiverr
FVRR
$339M
| $175K | ﹤0.01% |
900
| – | – |
|
|
SNV
967
DELISTED
Synovus
SNV
| $175K | ﹤0.01% |
5,425
+4,518
| +498% | +$131K |
|
968
Ingredion
INGR
$6.58B
| $174K | ﹤0.01% |
+2,220
| New | +$171K |
|
969
QuidelOrtho
QDEL
$838M
| $173K | ﹤0.01% |
965
-110,840
| -99% | -$24.6M |
|
970
Robert Half
RHI
$4.37B
| $171K | ﹤0.01% |
+2,743
| New | +$164K |
|
|
GES
971
DELISTED
Guess Inc
GES
| $167K | ﹤0.01% |
+7,413
| New | +$117K |
|
972
NovoCure
NVCR
$1.91B
| $167K | ﹤0.01% |
970
-877
| -47% | -$120K |
|
973
Tenable Holdings
TENB
$4.01B
| $164K | ﹤0.01% |
3,148
| – | – |
|
974
Innoviva
INVA
$1.48B
| $162K | ﹤0.01% |
13,098
-104,312
| -89% | -$1.13M |
|
|
ZEPP
975
Zepp Health
ZEPP
$69.7M
| $162K | ﹤0.01% |
3,433
-212,901
| -98% | -$10.6M |
|
Similar funds
QCM
Lazard Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Lazard Asset Management held 2,061 positions worth $79.1B, up 11% from $71.1B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Lazard Asset Management withdrew a net $5.86B in Q4 2020, closing 231 positions and reducing 465 holdings. Its most notable exit was Unilever NV New York Registry Shares, an estimated $112M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lazard Asset Management opened a new position in Sotera Health worth $100M.
- Lazard Asset Management's largest Q4 2020 buy was Sotera Health: 3,651,831 shares worth $100M.
- Lazard Asset Management added most to Sysco in Q4 2020, an estimated $273M increase.
- Lazard Asset Management's biggest Q4 2020 reduction was Pfizer, cutting an estimated $548M.
- Lazard Asset Management fully exited Unilever NV New York Registry Shares in Q4 2020, selling an estimated $112M.
- Lazard Asset Management's ten largest holdings make up 23% of its $79.1B portfolio in Q4 2020.
- Lazard Asset Management opened 445 new positions and closed 231 in Q4 2020.
- Lazard Asset Management's portfolio value rose 11% quarter-over-quarter to $79.1B.
Based on Lazard Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.